Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
|Videos|July 24, 2013
Effective Utilization Management Programs for Specialty Pharmacies
Specialty pharmacies can minimize "cost to treat" by identifying which specialty drugs have dose optimization opportunities, noted Michael Einodshofer, RPh, MBA, director of utilization management, Walgreens, at the 2013 PBMI Drug Benefit Conference.
Advertisement
Specialty pharmacies can minimize "cost to treat" by identifying which specialty drugs have dose optimization opportunities, noted Michael Einodshofer, RPh, MBA, director of utilization management, Walgreens, at the 2013 PBMI Drug Benefit Conference.
For more videos featuring Michael Einodshofer, click on our
Advertisement
Related to this article
With changes in Medicaid eligibility looming, hospitals must plan now to keep patient care gaps at bay.
Apitegromab-mstn is cleared as an add-on to SMN2-targeted treatment for patients aged 2 and older, directly addressing muscle loss.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Bladder Cancer Regimens Reshape Treatment Across Disease Stages
2
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
3
FDA Approves Levacetylleucine to Treat Ataxia in Adult, Pediatric Patients With A-T
4
Baseline Interferon Activity in Monocytes Predicts mRNA Vaccine Adverse Effects, Study Finds
5